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SUMMARY
AIMS AND BACKGROUND: This study of high-dose-rate brachytherapy to the lumpectomy site as the 
sole radiation presents longer-term results and toxicity of accelerated partial-breast irradiation, using 
three-dimensional treatment planning. 
MATERIALS AND METHODS: From March 2002 to July 2004, 25 patients were prospectively included 
in this study. Six patients were excluded because of defi nitive histology of lobular carcinoma or posi-
tive margin. The median age at the time of treatment was 63.2 years (range 44–77 years). Median fol-
low-up of all patients was 44 months (range 30–53 months) with a minimum follow-up of 30 months. 
Radiation was delivered using the high-dose-rate remote afterloader VariSource with 192Ir source. The 
patients received radiation twice a day at least 6 hours apart for a total of 10 fractions over fi ve days 
with a single dose of 3.4 Gy. The total dose was 34.0 Gy prescribed as a minimum peripheral dose to 
match or minimally exceed the volume defi ned by the surgical clips as seen on computed-tomography 
(CT) scans. Free-hand technique allows conformal placement of the catheters to the shape of the 
lumpectomy cavity. Side-effects and toxicity were scored using the EORTC/RTOG scale.
RESULTS: At a median follow-up of 44 months none of the women had developed in-fi eld breast 
recurrences, one patient had out-of-fi eld recurrences and one patient presented distant metastases. 
There were no regional nodal recurrences. In each woman, target volume size in cm3 (median 91.3 
cm3), dose volume histogram (DVH), and dose homogeneity index (DHI) were calculated. Median DHI 
was 0.42. Median volume of breast tissue receiving 100% of the prescription dose, V100, was 87%; 
and V150 48.5%. We noticed two treatment complications: haematoma and abscess in the place of 
the tumour bed after extirpation. At last follow-up, all patients rated the overall cosmetic outcome as 
excellent or good. 
CONCLUSIONS: This method is suitable only for patients with histologically confi rmed small tumours 
(<3 cm in diameter) without negative prognostic factors for local recurrence. We observed low treat-
ment-related morbidity and mild long-term toxicity with good treatment results.
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BACKGROUND
Breast conserving therapy is an attractive 
alternative to mastectomy for patients with 
Stage I and II breast cancer and it is now 
considered to be an equivalent therapy to 
mastectomy. The current standard of care 
for breast-conserving therapy includes a post-
lumpectomy course of whole-breast external 
beam radiotherapy (EBRT), which typically 
requires 5–7 weeks to complete. The purpose 
of radiotherapy (RT) is to prevent recurrence 
by eliminating residual foci of cancer that 
might remain in the surrounding breast tis-
sue. This conservative approach still has the 
same radical intent as the destructive surgery 
fi rst done by William Halstead over 100 years 
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ago. The main obstacle to wider acceptance of 
breast-conserving surgery is the dogma of 6-
7 weeks of postoperative radiotherapy, which 
has several disadvantages: the long course of 
treatment and very often distant abode of pa-
tients from a department of radiotherapy are 
a substantial burden on women [1, 2]. It has 
been estimated from patterns of care study by 
the American College of Surgeons that only 
50% of women in the United States who are 
eligible for breast-conserving surgery receive 
this form of treatment. Equally problematic, 
15% of women who should receive radiation 
after conservative treatment do not [3].
Accelerated partial-breast irradiation 
(APBI) may be defi ned as any scheme that 
delivers radiotherapy to the tumour site and 
some surrounding tissue over a short over-
all period (5-8 days). Among the approaches 
described to date using brachytherapy to ac-
complish this are the following: low-dose rate 
(LDR) or high-dose rate (HDR) brachythera-
py using interstitial implantation or a balloon 
catheter (MammoSite), and single-fraction in-
traoperative irradiation using 50 kV orthovolt-
age radiation (Intrabeam) or electrons 4–12 
MeV (Mobetron, Novac-7) [2, 4]. Irradiation 
of the tumour bed only is being investigated in 
several clinical trials. The number of studies 
with median follow-up times of about 6 years 
using mainly interstitial high-dose rate APBI, 
8–10 fractions, and total doses of 32 to 34 Gy 
have found low rates of breast recurrence and 
good cosmetic outcome. However, many cen-
tres do not have signifi cant brachytherapy ex-
perience [5, 6, 7, 8, 9]. 
Long-term results of the use of three-di-
mensional conformal planning of periopera-
tive interstitial sole brachytherapy of early 
stage breast carcinoma including late effects 
and morbidity are presented. 
MATERIALS AND METHODS 
Sole conformal perioperative interstitial 
brachytherapy was delivered to patients with 
early stage breast carcinoma. From March 
2002 to July 2004, 25 patients were prospec-
tively included in this study, which was ap-
proved by the Ethics Committee of Masaryk 
Memorial Cancer Institute. All patients gave 
informed consent. Six patients were excluded 
because of defi nitive histology of lobular car-
cinoma or positive margin. The median age 
at the time of treatment of the 19 women in 
this pilot study was 63.2 years (range: 44–77 
years). Median follow-up of all patients was 44 
months (range: 30-53 months).
Study objectives. The objective is to es-
tablish methods of perioperative brachyther-
apy in clinical  practice, and evaluate treat-
ment complications, cosmetic effect and local 
control. Eligibility criteria and diagnostic 
work-up. Patients with invasive lobular histol-
ogy were excluded. Initially all patients were 
axillary node negative (only 3 patients had 1 to 
3 axillary nodes positive). Eligibility criteria 
included histology of adenocarcinoma, clinical 
stage T1-T2 (tumour size <3 cm), and axillary 
node-negative breast cancer with microscopic 
resection margins negative for ductal carci-
noma. Pretreatment work-up included clinical 
examination, mammography and breast and 
axillary ultrasonography with biopsy of breast 
tumour, chest X-ray, liver ultrasonography, 
gynaecological examination and bone scintig-
raphy, pretreatment CT of breast, serum CEA 
and Ca15-3 levels, and blood tests. 
Patient population, follow-up. Patient 
characteristics are summarized in Table 1. The 
follow-up schedule included breast examina-
tion every 3 months. Mammography was done 
at 6 months after brachytherapy and then once 
a year together with ultrasonography. Cosmetic 
effect was assessed every 3 months. 
Surgery and brachytherapy. In this group 
the patients underwent standard lumpectomy. 
During the surgery the needles were inserted 
into the tumour bed and nylon catheters were 
threaded through the needles (free-hand tech-
nique). The margins of the cavity were marked 
by clips. A very important, maybe the most im-
portant, aspect was the correct and accurate 
defi nition of the target volume. For this reason 
we used a combination of preoperative (pre-
implant) CT scans of 2–5 mm intervals and 
2 mm thickness to identify the tumour with 
postoperative (postimplant) CT scans with 
the location of clips and applicators. Radiation 
was delivered using the high-dose rate remote 
afterloader VariSource with 192Ir source and 
perioperative interstitial application of mul-
ticatheters. The patients received radiation 
twice a day at least 6 hours apart for a total of 
10 fractions over fi ve days with a single dose of 
3.4 Gy. The total dose was 34.0 Gy prescribed 
as a minimum peripheral dose to match or 
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minimally exceed the volume defi ned by the 
surgical clips as seen on CT scans. We used 
the method of geometric optimisation which 
allows the calculation of dose distribution in 
relation to the target. During brachytherapy, 
antibiotics were used as a prophylaxis. After 
fi nishing brachytherapy (usually within 10 
days after the surgery) the catheters were re-
moved. The patients were regularly observed.
Before the operation, CT examination was 
done in the quadrant with tumourous infi ltrate. 
After total tumour extirpation plastic tubules 
for interstitial brachytherapy and X-ray con-
trast clips indicating cavity walls were preop-
eratively placed into the tumour bed. Placing 
of the indicators was done using needles with 
free-hand technique. The number and disloca-
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Characteristics Value 1
Age (years) 65 (48; 80)
Follow-up (months) 44 (30; 53)
Region
  m. dx N = 8 (42.1 %)
  m. sin N = 11 (57.9 %)
Parameters of radiotherapy
  Two levels of catheters N = 16 (84.2 %)
  Number of catheters (mean) 9 (5; 14)
  Dose (Gy)/Fraction 3.4 (3.0; 4.0)
  Number of fractions 10 (8; 10)
  PTV (cm3) 95.7 (40.1; 304.4)
  Dosemin (Gy) 60.0 (32.0; 77.6)
  Dosemax (Gy) 1029.6 (574.1; 2084.6)
  Mean (Gy) 165.8 (129.6; 198.7)
  Modal (Gy) 118.4 (95.3; 177.5)
  Median (Gy) 147.0 (115.2; 175.4)
  STD 2.46 (0.67; 3.54)
  V85 (%) 96.3 (82.0; 99.0)
  V100 (%) 88.0 (65.0; 95.5)
  V150 (%) 48.0 (24.0; 65.0)
  DHI 0.43 (0.31; 0.65)
Chronic changes N = 12 (63.1 %)
  Fibrosis (degree 1) N = 8 (42.1 %)
  Fibrosis (degree 2) N = 2 (10.5 %)
  Skin changes (degree 1) N = 3 (15.7 %)
  Skin changes (degree 2) N = 1 (5.3 %)
1 Continuous variables are expressed as median with MIN/MAX values (in parentheses). 
Binary variables are summarized as N and % of given category. 
1 No. of cells is expressed in log scale as arithmetic mean and standard error of trans-
formed values (Xtransformed = ln[X])
Table 1. Overall characteristics of patients (N = 19) tion of conductors depends on the target vol-
ume. One or more level puncture was used. 
With an interval of 3 to 5 days after the opera-
tion, CT planning examination was done. The 
scans were transferred to the planning system 
BrachyVision. The system enabled construc-
tion and spatial view of all the important tis-
sues and structures, especially the skin, lungs 
and ribs. In every section there was also the 
charted position of the applicators. The target 
volume (tumour bed with security border) in 
every cut was determined on the basis of pre-
operative CT examination, placing of X-ray 
contrast clips and position of applicators. The 
planning system enabled a three-dimensional 
view of the shape of the target volume and 
placing of conductors. Then, in the planning 
mode, optimisation of dose distribution and 
setting of “dwell times” was carried out. Us-
ing so-called local shift of reference isodoses 
and adjusting the times in every position of 
the source, we could adapt the shape of ref-
erence isodoses to the target volume (confor-
mal “inverse” planning). Radiotherapy was 
started within 5 days after the operation after 
defi nitive histology. Except for local control of 
the illness, the cosmetic effect of this curative 
method was also carefully evaluated.
Statistical methodology. Standard sum-
mary statistics were used to express values of 
measured parameters (median supplied with 
MIN/MAX values, mean with standard er-
ror and frequency analysis). Differences be-
tween two groups of patients with and without 
chronic changes were tested using standard 
t-test for two independent samples.
RESULTS
In the study 19 patients were evaluated. None 
of the women has died. None of the women 
developed in-fi eld breast recurrences; one 
patient had out-of-fi eld recurrences. Distant 
metastases were found in one patient. There 
were no regional nodal recurrences. 
The median volume encompassed by the 
34.0 Gy isodose shell was 91.3 cm3 (range 40.1-
304.4 cm3). In each woman, target volume size 
in cm3 (median 91.3 cm3), dose volume his-
togram (DVH), and dose homogeneity index 
(DHI) were calculated. Median DHI was 0.42 
(Table 1). Median volume of breast tissue re-
ceiving 100% of the prescription dose, V100, 
was 87%; and V150 48.5%.
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In all the women, the dose on the skin did 
not exceed 50% of the applied dose on the 
reference isodose. We noticed two treatment 
complications: haematoma and abscess in the 
region of the tumourous bed after extirpation 
(2 of 19 pts, 10.5 %). Data on the cosmetic out-
come from treatment continues to be favour-
able. At at least 30 months of follow-up, all 
patients rated the overall cosmetic outcome as 
excellent or good (EORTC, grade 0-2). No G3 
or G4 acute or late toxicity were observed. 
Late chronic changes were observed in 
63.1% (12 patients): fi brosis G1 (EORTC/RTOG 
scale) was seen in 42.1% (8 pts), fi brosis G2 in 
10.5% (2 pts). Skin changes were observed in 
15.7% (3 pts): G2 toxicity (mild teleangiecta-
sia) was seen in 5.3% (1 pt) (Table 1). Fat ne-
crosis was not observed.
Therapy-related features were analyzed for 
their relationship to cosmetic outcome and 
toxicity rating. The analysis was done only 
for fi brosis due to the low number of patients 
presenting with late skin toxicity. Therapy-
related features analyzed were number of 
fractions, number of catheter levels, number 
of applicators, PTV volume, dose parameters, 
standard deviation (STD), dose-homogeneity 
index (DHI), V85, V100 and V150 (Table 2).
Fibrosis was signifi cantly associated with 
STD and inversely associated with number of 
applicators, single dose per fraction and mod-
al dose applied. No association was found with 
other parameters.  
DISCUSSION
Adjuvant radiotherapy after conservative 
breast surgery remains a question which has 
not been answered yet and its indication and 
volume are the topics of a variety of studies. 
Ways are being sought to shorten the total du-
ration of the therapy, to reduce the toxicity, to 
improve the comfort of patients and to reduce 
the treatment costs, while safety and effec-
tiveness of the treatment must be preserved. 
One of the possibilities for some of the pa-
tients is to dose the radiation only to the bed of 
the tumour – without the necessity of irradiat-
ing the whole breast – either intraoperative ir-
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Characteristics Patients without fi brosis (n = 9) Patients with fi brosis (n = 10)
Age (years) 66 (3) 64 (2)
Region
  m. sin N = 6 (66.7 %) N = 4 (40 %)
Parameters of radiotherapy
  Two levels of catheters N = 10 (100 %) N = 6 (60 %)
  Number of catheters (mean) 9.6 (0.4)* 8.2 (0.7)*
  Dose (Gy)/Fraction 3.6 (0.1)* 3.3 (0.1)*
  Number of fractions 8.7 (0.6) 7.4 (0.8)
  Number of fractions (=10) N = 5 (55.6 %) N = 6 (50 %)
  PTV (cm3) 95.8 (8.0) 112.5 (18.9)
  Dosemin (Gy) 58.2 (3.3) 60.7 (2.3)
  Dosemax (Gy) 1027.2 (124.5) 1183.4 (101.3)
  Mean (Gy) 166.5 (5.4) 164.6 (4.1)
  Modal (Gy) 134.7 (7.3)* 116.4 (4.9)*
  Median (Gy) 151.2 (4.5) 145.5 (4.3)
  STD 2.1 (0.2)* 2.7 (0.2)*
  V85 (%) 95.2 (1.4) 93.9 (1.3)
  V100 (%) 87.6 (2.3) 84.5 (2.3)
  V150 (%) 50.0 (3.3) 46.3 (2.8)
  DHI 0.43 (0.03) 0.46 (0.02)
1 Continuous variables are expressed as arithmetic mean with standard error (in parentheses). Binary variables are summarized as N and % of given category. 
* Mark for statistical signifi cance between patients with and without fi brosis (t-test, p < 0.05)
1 No. of cells is expressed in log scale as arithmetic mean and standard error of transformed values (Xtransformed = ln[X])
2 Test of signifi cance of differences between two compared methods (t-test)
Table 2. Characteristics of patients with and without fi brosis 
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radiation or interstitial brachytherapy, which 
is a more frequently used method.
In randomized clinical trials of conservative 
breast surgery with or without whole-breast ra-
diation the percentages of recurrences in the 
lumpectomy site ranged from 5 to 12% for wom-
en who had radiation and from 25 to 35% for 
women who did not have radiation [6, 7, 9, 10]. 
At 57 months’ median follow-up, Polgar et 
al. [11] described two local recurrences as 
“remote” from the implanted volume among 
45 patients treated with HDR brachytherapy 
(30.3 Gy or 36.4 Gy in 7 fractions over 5 days 
with 2 cm margins). 
Perera et al. [12] reported a small (39 pa-
tients), single-institution, pilot study of HDR 
brachytherapy (37.2 Gy in 10 fractions over 
one week) as a sole modality of adjuvant radio-
therapy after breast-conserving surgery. The 
recurrence rate after surgery in their series 
was 16.2% (6 patients) at 5 years. Only 2 pa-
tients (5.1%) had in-fi eld recurrences. All ip-
silateral breast recurrences were salvaged by 
mastectomy (4 patients) or repeat lumpectomy 
(2 patients) and whole-breast radiation. The 5-
year overall survival was 86%. 
Major et al. [13] defi ned planning treatment 
volume (PTV) for using HDR brachytherapy 
for partial breast irradiation as the lumpec-
tomy cavity and 1 cm margin (the average vol-
ume of PTV was 54.5 cm3). The median value 
of V100 (dose points were optimized with con-
formal system) was 0.86. 
Ott et al. [14] reported that only one of 69 
patients (1.4%) in the study with interstitial 
multicatheter brachytherapy implants devel-
oped a bacterial infection of the implant. No 
other perioperative complications (bleeding, 
haematoma) were observed.
Ott et al. [15] reported the perioperative 
morbidity, acute and late toxicity and cos-
metic outcomes in 3-year results of the Ger-
man-Austrian phase II trial of partial breast 
irradiation. In 274 patients they observed pe-
rioperative complications in 5.5% and 3-year 
local control in 99.3%. Acute toxicity (Grade 
1–2 radiodermatitis) was seen in 6.6% and late 
side effects Grade ≥ 3 (fi brosis, teleangiecta-
sia) occurred in 1.8%. Cosmetic results were 
excellent/good in 94%.
Wazer et al. [16] analyzed clinical and 
therapy-related features for their relation-
ship to cosmetic outcome and toxicity rating 
in a group of 75 women. Suboptimal cosmetic 
outcome was signifi cantly associated with the 
number of source dwell positions, V150 and 
V200, and inversely associated with DHI (0.77 
vs. 0.73, p=0.05). The risk of Grade 1/2 skin 
toxicity was signifi cantly associated with V150 
and V200 and inversely associated with DHI 
(0.77 vs. 8.71, p=0.009). The risk of Grade 0/1 
vs. Grade 2–4 subcutaneous toxicity was sig-
nifi cantly associated only with a lower value of 
DHI (0.77 vs. 0.73, p=0.02). The use of adria-
mycin-based chemotherapy after accelerated 
partial breast irradiation was found to be 
associated with a signifi cant increase in the 
incidence of higher-grade skin toxicity and a 
higher risk of fat necrosis and suboptimal cos-
metic outcomes.
Kuske et al. [17] analyzed the toxicity of 
RTOG 95-17. From 99 women, 33 were treated 
with LDR APBI (45 Gy in 3.5–5 days), and 66 
were treated with HDR APBI (34 Gy in 10 
twice-daily fractions for 5 days). Chemother-
apy (>or=2 weeks after APBI) and/or tamoxi-
fen was given at the discretion of the treating 
physicians. Of the 66 patients treated with 
HDR APBI, 3% had Grade 3 or 4 acute toxic-
ity (erythema, oedema, tenderness, pain and 
infection), and of the 33 patients treated with 
LDR 9% had G3 or G4 toxicity. Late toxicities 
included skin thickening, fi brosis, breast ten-
derness and teleangiectasia. No patient expe-
rienced Grade 4 toxicity. The rate of Grade 3 
toxicity was 18% for the LDR and 4% for the 
HDR group. Patients receiving chemotherapy 
had a greater rate of Grade 3 toxicity.
Kaufman et al. [18] published an updated 
analysis of survival, recurrence rate and tox-
icity for  a cohort of women with early-stage 
breast cancer treated with high-dose-rate in-
terstitial brachytherapy for accelerated partial 
breast irradiation between August 1997 and July 
2001. There were 32 women with 33 breast can-
cers (T1-2 tumours with </= 3 axillary nodes 
positive, nonlobular histology, negative surgi-
cal margins, and no evidence of extracapsular 
lymph node extension). The actuarial local re-
currence was 6.1% (3 pts) at 5 years, which is 
comparable to that seen in conventional whole 
breast series; all three were elsewhere failures 
within the treated breast. For the purpose of 
analysis, toxicity scores were assigned to each 
of four follow-up intervals: </=6 months, >6 but 
</=24 months, >24 but </=60 months, and >60 
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months. Fat necrosis was not seen in the first 6
months after treatment, then appeared in 27.3%
ofpatients from 6 to 24 months, 28.1% from 24
to 60 months, and 17.9% beyond 60 months.
Skin toxicity appeared to stabilize with longer
follow-up: the percentage of patients showing
any degree of skin toxicity was 69.7%, 33.3%,
40.6%, and 28.6% at each successive time in-
terval. Subcutaneous toxicity increased beyond
60 months: moderate to severe subcutaneous
toxicity was seen in 15.2%, 18.2%, 18.8%, and
35.7%of patients successively. The percentage
of patients with less than excellent cosmetic
outcome improved beyond 60 months (21.2%,
21.2%, 21.9%, and 11.1% successively). Only 1
patientexperienced more than mild pain at any
time. The percentage of patients experiencing
any degree of pain improved over time (30.3%,
33.3%,18.8%,17.9%).
Polgar et al. [19] reported the seven-year
results of a comparative study of HDR brachy-
therapy alone versus whole breast radio-
therapy after breast-conserving surgery. 45
patients with T1 NO -N1mi, nonlobular breast
cancer without the presence of an extensive
intraductal component and with negative sur-
gicalmargins were treated with APBI. A total
dose of 30.3 Gy (n=8) and 36.4 Gy (n=37) in
seven fractions within 4 days was delivered to
the tumour bed plus a 1-2 ern margin. Dur-
ing the same period, 80 patients, who were
treated with 50 Gy WBRT with or without a
10-16 Gy TBB, were selected as controls. The
differencesin the 5- and 7-year actuarial rates
of ipsilateral breast recurrence were not sta-
tistically significant among patients treated
with APBI (4.4% and 9.0%), WBRT (4.7% and
14.8%) and WBRT + TBB (5.7% and 9.5%). No
statistically significant difference in either
the7-year probability of relapse-free survival
or cancer-specific survival was found. The
ratesofasymptomatic fat necrosis were 20.0%
and 20.6% for APBI and WBRT, respectively.
Symptomatic fat necrosis occurred in 1 pa-
tient (2.2%) treated with APBI. The incidence
ofGrade 2 or worse late radiation side effects
was similar for both groups.
As a result of the small number of patients
with a relatively short follow-up in the group ,
theevaluationof our results - concerning both
thetoxicity and the local control of the illness
- is difficult. Acute toxicity of the treatment
was low (two out of twelve patients); further-
more the influence of the surgery and surgical
equipment can hardly be differentiated from
the influence of the radiotherapy itself.
The small number of patients in our group
who showed signs of skin toxicity while being
observed does not allow any appraisal of the
influence of the dosimetric characteristics on
their incidence. As for fibrosis (subcutaneous
toxicity), standard deviation (STD) and the
number of applicators (inversely associated
with fibrosis) were found to be statistically
relevant in our file. We observed quite fre-
quent occurrence of fibrosis G1 (42.1% of the
patients); nevertheless this fact had no nega-
tive impact on patients' evaluation of the cos-
metic effect. The incidence of other late side
effects of the treatment was low.
We did not evaluate the cosmetic effect of
sole HDR-BRT in comparison with the effect
achieved with WBRT (± TBB). It was at least
similar, without the occurrence of G3 or toxic-
ity, however. Because of the small number of
patients it is hard to evaluate the local control
in comparison with WBRT; we did not regis-
ter any in-field recurrence though . Regarding
indication of sole BRT after breast-conserving
surgery on the number of nodes affected (no
nodes vs. </= 3 axillary nodes positive) we in-
cluded the patients with </= 3 axillary nodes
positive and we did not register any nodal re-
currence.
CONCLUSIONS
In conclusion, sole perioperative brachyther-
apy has a number of positives. It shortens the
adjuvant therapy, helps prevent delay in appli-
cation of other therapeutic modalities (chemo-
therapy and /or further radiotherapy) and im-
proves the treatment sequencing, all of which
reduce hospitalization time and treatment
costs. Advantages of 3D conformal planning
of interstitial brachytherapy are: exact imag-
ing of target volume and its relation to other
critical structures (skin, rib s, lung), and also
accurate optimisation, imaging and evaluation
of dose distribution. Owing to the risk of un-
dertreatment, this method is only suitable for
patients with a small histologically confirmed
carcinoma without negative prognostic fac-
tors of local recurrence. Accelerated partial
breast irradiation using interstitial high-dose -
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rate implants, with proper patient selection
and quality assurance, yields similar results
and toxicity to those achieved with standard
breast-conserving therapy while shortening
the total treatment duration. Both the objec-
tive and the subjective (evaluated by the pa-
tient herself) cosmetic effects obtained by the
two therapy methods are comparable. From
the patient's point of view the final cosmetic
results are not the least important thing; in
fact for some of them it is a matter of great
importance. Using this technique of irradia-
tion we achieved some really good cosmetic
results. However, local disease control com-
parable with results achieved with standard
adjuvant radiotherapy has to be verified in a
randomized clinical study.
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